This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
ACP and other professional medical societies disagree on a proper target for the long-term benefits of glucose control.
About 20 million Americans currently have type 2 diabetes, three times more than in 1980. Diabetes is a major risk factor for stroke and hea...
This regulatory update covers a recall of a compounding pharmacy's products due to mold and approval of a sodium-glucose co-transporter for diabetes.
The evidence of an association between women with big waists and the onset of diabetes got a little bit more solid, thanks to a study of mor...
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a new intravenous drug for bacterial skin and
Any type 2 diabetic is eventually going to need oral medications, and some on oral medications may eventually progress to needing insulin. The regimens are complex and vary from patient to patient. Learn how to individually tailor such decisions.
Regular primary care providers treat diabetic patients more proactively than covering physicians or midlevel providers, shown by an increase...
This update covers new warnings on the entire class of opioids and approval of the first leadless pacemaker approved to treat heart rhythm disorders.
A recent report might shed some diagnostic insight on the profound fatigue, unrefreshing sleep, and other nagging symptoms that could indicate myalgic encephalomyelitis/chronic fatigue syndrome.